Skip to main content
Clinical Trials/KCT0005483
KCT0005483Not yet recruiting未知

A randomized, prospective, comparative study of the effectiveness of prophylactic entecavir treatment for HBV reactivation in past HBV infected patients with hematopoietic stem cell transplantation

The Catholic University of Korea, Seoul St. Mary's Hospital0 sites164 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
未知
Status
Not yet recruiting
Enrollment
164

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional Study

Eligibility Criteria

Ages
19?(Year) to 70?(Year) (—)
Sex
All

Inclusion Criteria

  • 1. Age: 19 - 70
  • 2. patients receiving hematopoietic stem cell transplantation
  • 3. HBV serologic test: HBsAg (-), anti-HBc IgG (+)
  • 4. ECOG performence: 0-2
  • 5. patients with informed consent

Exclusion Criteria

  • 1. HBV DNA (+, =10 IU/mL) at the time of screening
  • 2. Receiving hematopoietic stem cell transplantation from donor with HBsAg+
  • 3. Combined other chronic liver disease (severe alcoholics, autoimmune hepatitis, chronic hepatitis C etc.)
  • 4. HIV (+)
  • 5. Previous antiviral therapy history for chronic hepatitis B
  • 6. Other concomitant malignancy
  • 7. combined autoimmune disease (rheumatic arthritis, SLE etc)
  • 8. CTP class B, C
  • 9. Decompensated complications (ascites, hepatic encephalopathy etc.)
  • 10. active tuberculosis

Investigators

Similar Trials